Payment overview · 2025
General Payments
$1,462.19
46 reported records · 16 companies
Healthcare provider profile · identity verified
Lance I Austein, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1366430969
Verified facts
What the public records show
CMS Open Payments records show Lance I Austein, MD received $1,462.19 in general payments during 2025 across 46 reported records.
Lilly USA, LLC accounted for 16.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $241.05 | 16.5% | 10 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $217.99 | 14.9% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $212.81 | 14.6% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $135.13 | 9.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $111.60 | 7.6% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $110.17 | 7.5% | 4 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $90.69 | 6.2% | 3 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $80.03 | 5.5% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $65.30 | 4.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $51.40 | 3.5% | 3 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $45.78 | 3.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $30.14 | 2.1% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $20.02 | 1.4% | 1 | 2025 |
| Orexo US, Inc. | Unresolved — no canonical attribution shown | $18.14 | 1.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.68 | 1.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.26 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,369.20 | 45 |
| Education | $92.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $241.05 | 10 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $212.81 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $209.55 | 9 | 2025 |
Source payment records
|
|||||
| Jakafi Normalized: jakafi |
Drug | Incyte Corporation | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $121.87 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $110.17 | 4 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $90.69 | 3 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $80.03 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $72.21 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $65.30 | 2 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $45.78 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $39.39 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $36.94 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $30.14 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.51 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| Zubsolv Normalized: zubsolv |
Drug | Orexo US, Inc. | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.46 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.46 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.46 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.26 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.26 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 84 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 166 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
166 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
84 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 294 | 77 |
| Alprazolam | Alprazolam | 231 | 36 |
| Mounjaro | Tirzepatide | 166 | 29 |
| Levothyroxine Sodium | Levothyroxine Sodium | 147 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 136 | 28 |
| Amlodipine Besylate | Amlodipine Besylate | 131 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 131 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 124 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 120 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 107 | 16 |
| Gabapentin | Gabapentin | 98 | 18 |
| Metformin Hcl | Metformin Hcl | 98 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 96 | 22 |
| Clonazepam | Clonazepam | 92 | 14 |
| Eliquis | Apixaban | 84 | 15 |
| Simvastatin | Simvastatin | 81 | 24 |
| Lisinopril | Lisinopril | 77 | 21 |
| Trazodone Hcl | Trazodone Hcl | 76 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 69 | 14 |
| Prednisone | Prednisone | 68 | 41 |
| Montelukast Sodium | Montelukast Sodium | 59 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 56 | suppressed |
| Omeprazole | Omeprazole | 55 | 11 |
| Famotidine | Famotidine | 54 | 15 |
| Ozempic | Semaglutide | 53 | suppressed |
| Azithromycin | Azithromycin | 52 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 52 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | suppressed |
| Valsartan | Valsartan | 50 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 48 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 48 | suppressed |
| Glimepiride | Glimepiride | 48 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 47 | suppressed |
| Meloxicam | Meloxicam | 47 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 46 | 12 |
| Ibuprofen | Ibuprofen | 46 | 14 |
| Lorazepam | Lorazepam | 46 | 17 |
| Celecoxib | Celecoxib | 45 | suppressed |
| Losartan Potassium | Losartan Potassium | 44 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 43 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 43 | 11 |
| Finasteride | Finasteride | 41 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | suppressed |
| Trulicity | Dulaglutide | 38 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 36 | suppressed |
| Carvedilol | Carvedilol | 36 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 35 | suppressed |
| Allopurinol | Allopurinol | 34 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | suppressed |
| Diazepam | Diazepam | 33 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 30 | suppressed |
| Temazepam | Temazepam | 30 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Levofloxacin | Levofloxacin | 27 | 19 |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Furosemide | Furosemide | 26 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Methadone Hcl | Methadone Hcl | 23 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 21 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 15 |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 20 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | 13 |
| Digoxin | Digoxin | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Tadalafil | Tadalafil | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 12 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Potassium Chloride | Potassium Chloride | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,462.19 · 46 records | Lilly USA, LLC | ABRYSVO, Auvelity, BREZTRI, BRIXADI, CAPLYTA, COMIRNATY, ELIQUIS, FARXIGA, Jakafi, LOREEV XR, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, REPATHA, REXULTI, Rybelsus, SUBLOCADE, TRELEGY ELLIPTA, VIVITROL, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND, Zubsolv | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error